Previous 10 | Next 10 |
home / stock / agnpf / agnpf news
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) ...
Algernon Pharmaceuticals (AGNPF) posts promising data from its phase 2b/3 study testing NP-120 (Ifenprodil) in treating patients with COVID-19.In the study, measurement from baseline to day five showed that IL-6, one of the biomarkers that was measured, was reduced in the 20 mg treatment...
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company announces that NP-120 (Ifenpro...
Algernon Pharmaceuticals (AGNPF) announces that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis ((IPF)) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).The purpose of the 20 patient proof-of-concept trial is to determ...
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company is pleased to announce that it...
Algernon Pharmaceuticals (AGNPF) has filed an end of Phase 2 meeting request (EOP2) with the FDA, based on the completion of the Phase 2b part of its late-stage COVID-19 trial of NP-120 (Ifenprodil). The purpose of an EOP2 meeting is to facilitate interaction between the FDA and sponsors who ...
VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it has filed an end of ...
VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans t...
VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has app...
Algernon Pharmaceuticals (AGNPF) announces topline data from the Phase 2b part of its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil).The company tested two doses of the treatment, a 20 mg and 40 mg dose of Ifenprodil.At Day 15 of the study (the last day of treatment) there was 0% mortality ...
News, Short Squeeze, Breakout and More Instantly...
Algernon Pharmaceuticals Inc - Class A Company Name:
AGNPF Stock Symbol:
OTCMKTS Market:
Algernon Pharmaceuticals Inc - Class A Website:
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved...
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...